Vedolizumab has been studied in 2,700 patients in nearly 40 different countries. It is designed to treat moderate to severe Crohn’s disease and ulcerative colitis.
More Articles on Gastroenterology:
MIT Researchers Develop 3-D Colonoscopy Technique
Florida Medical Association Names Dr. Alan Harmon President
New York Gastroenterology Associates Opens Scarsdale Office
